OTC Markets OTCPK - Delayed Quote USD

PureTech Health plc (PTCHF)

Compare
1.9910 0.0000 (0.00%)
At close: October 29 at 4:00 PM EDT
Loading Chart for PTCHF
DELL
  • Previous Close 0.0000
  • Open 1.9200
  • Bid 1.9200 x 312700
  • Ask 2.0800 x --
  • Day's Range 1.9200 - 1.9200
  • 52 Week Range 1.6900 - 3.0000
  • Volume 1,500
  • Avg. Volume 4,182
  • Market Cap (intraday) 476.687M
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date Aug 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.50

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

www.puretechhealth.com

90

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PTCHF

View More

Performance Overview: PTCHF

Trailing total returns as of 10/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PTCHF
16.34%
FTSE 100
5.83%

1-Year Return

PTCHF
5.34%
FTSE 100
12.25%

3-Year Return

PTCHF
58.52%
FTSE 100
13.08%

5-Year Return

PTCHF
38.36%
FTSE 100
12.02%

Compare To: PTCHF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PTCHF

View More

Valuation Measures

Annual
As of 7/12/2024
  • Market Cap

    472.76M

  • Enterprise Value

    -5.26M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    847.33

  • Price/Book (mrq)

    1.51

  • Enterprise Value/Revenue

    348.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -13.39%

  • Return on Equity (ttm)

    -22.07%

  • Revenue (ttm)

    468k

  • Net Income Avi to Common (ttm)

    -82.47M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    500.42M

  • Total Debt/Equity (mrq)

    47.27%

  • Levered Free Cash Flow (ttm)

    -1.52M

Research Analysis: PTCHF

View More

Revenue vs. Earnings

Revenue 144k
Earnings -20.89M
 

Analyst Price Targets

3.19
3.50 Average
1.9910 Current
4.08 High
 

Company Insights: PTCHF

People Also Watch